Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Clint D. Bahler, MD

Advertisement

Articles by Clint D. Bahler, MD

Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026

ByClint D. Bahler, MD
June 5th 2026

Clint D. Bahler, MD, reflects on key prostate cancer themes from AUA 2026, including the shift toward more personalized care.

Advertisement

Latest Updated Articles

  • Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
    Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026

    June 5th 2026



Advertisement
Advertisement

Trending on Urology Times

1

Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC

2

Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026

3

Belzutifan plus lenvatinib maintains PFS benefit vs cabozantinib in advanced ccRCC

4

Comparing PSMA-PET agents: What urologists should know

5

Chad Ritch, MD, on using PSMA-PET to guide treatment decisions

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us